Thromboembolic complications of percutaneous transluminal coronary angioplasty for myocardial infarction. 1987

J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle

To determine the incidence of thromboembolic complications of percutaneous transluminal coronary angioplasty (PTCA) in the setting of recent and acute myocardial infarction, the clinical sequelae and coronary angiographic findings were examined in a series of 13 patients who underwent PTCA either as acute intervention during the infarction or as treatment for recurrent myocardial ischemia that occurred soon after the initial completed infarction. In all cases, the angiographic appearance in the infarct-related artery was that of thrombus in the setting of total or subtotal occlusion. Balloon dilatation without antecedent thrombolytic therapy, was performed in 14 arteries and was successful in establishing reperfusion with reduction of the degree of intraluminal narrowing to less than 50% in all cases. Residual thrombus at the site of inflation was noted in two cases (15%), and embolization was noted in four cases (29%), for an incidence of complication of 44%. In five of six instances in which either residual thrombus or embolization were noted, the initial infarction had occurred greater than 24 h before. In only one of seven cases in which PTCA was used as acute intervention during infarction of less than 4 h duration was the presence of residual thrombus noted after PTCA. Therefore, these findings suggest that thromboembolic complications after PTCA in the setting of recent or acute myocardial infarction are uncommon when the syndrome is less than 4 h duration; however, complications are relatively frequent when infarction has occurred greater than 24 h before. PTCA as a primary intervention in this latter setting should be approached cautiously.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003328 Coronary Thrombosis Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION. Thrombosis, Coronary,Coronary Thromboses,Thromboses, Coronary
D004155 Diphenhydramine A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects. Benhydramin,Diphenylhydramin,2-Diphenylmethoxy-N,N-dimethylethylamine,Allerdryl,Benadryl,Benylin,Benzhydramine,Dimedrol,Diphenhydramine Citrate,Diphenhydramine Citrate (1:1),Diphenhydramine Hydrochloride,Diphenylhydramine,Dormin,Citrate, Diphenhydramine,Hydrochloride, Diphenhydramine
D005260 Female Females
D005996 Nitroglycerin A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. Glyceryl Trinitrate,Anginine,Dynamite,Gilustenon,Nitrangin,Nitro-Bid,Nitro-Dur,Nitrocard,Nitroderm,Nitroderm TTS,Nitroglyn,Nitrol,Nitrolan,Nitrong,Nitrospan,Nitrostat,Perlinganit,Susadrin,Sustac,Sustak,Sustonit,Transderm Nitro,Tridil,Trinitrin,Trinitrolong,Nitro Bid,Nitro Dur,NitroBid,NitroDur,Trinitrate, Glyceryl
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
April 1993, Internal medicine (Tokyo, Japan),
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
November 1989, Cardiology clinics,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
April 2003, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
August 1994, Nihon rinsho. Japanese journal of clinical medicine,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
April 2003, Nihon rinsho. Japanese journal of clinical medicine,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
June 1984, The American journal of cardiology,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
December 1988, Journal of cardiology,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
September 1997, Zhonghua nei ke za zhi,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
March 1990, Ugeskrift for laeger,
J Cameron, and M Buchbinder, and L Wexler, and S N Oesterle
April 1984, American heart journal,
Copied contents to your clipboard!